Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study

Oral semaglutide is the first oral glucagon‐like peptide‐1 receptor agonist for the treatment of type 2 diabetes, and showed significant benefits in glycaemic control and weight reduction versus active comparators in the PIONEER phase 3a randomized controlled trial programme. In this retrospective s...

Descripción completa

Detalles Bibliográficos
Autores principales: Aroda, Vanita R., Faurby, Mads, Lophaven, Søren, Noone, Josh, Wolden, Michael Lyng, Lingvay, Ildiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453868/
https://www.ncbi.nlm.nih.gov/pubmed/34060209
http://dx.doi.org/10.1111/dom.14453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453868/
https://www.ncbi.nlm.nih.gov/pubmed/34060209
http://dx.doi.org/10.1111/dom.14453

Ejemplares similares